236 related articles for article (PubMed ID: 2849248)
21. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation.
Cho KJ; Vinik AI
Radiology; 1990 Nov; 177(2):549-53. PubMed ID: 2171015
[TBL] [Abstract][Full Text] [Related]
22. [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours].
Colao A; Pulcrano M; Dorato M; Müller F; Rossi FW; De Martino MC; Biondi B; Lombardi G
Minerva Endocrinol; 2001 Dec; 26(4):231-8. PubMed ID: 11782708
[TBL] [Abstract][Full Text] [Related]
23. Octreotide, a new somatostatin analogue.
Katz MD; Erstad BL
Clin Pharm; 1989 Apr; 8(4):255-73. PubMed ID: 2653711
[TBL] [Abstract][Full Text] [Related]
24. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide.
Creutzfeldt W; Bartsch HH; Jacubaschke U; Stöckmann F
Acta Oncol; 1991; 30(4):529-35. PubMed ID: 1713038
[TBL] [Abstract][Full Text] [Related]
25. A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review).
Comaru-Schally AM; Schally AV
Int J Oncol; 2005 Feb; 26(2):301-9. PubMed ID: 15645113
[TBL] [Abstract][Full Text] [Related]
26. Hypercalcaemia caused by a carcinoid tumour.
Brzozowska MM; Wolmarans L; Conaglen JV
Intern Med J; 2009 Jun; 39(6):415-8. PubMed ID: 19580622
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin analogs in the management of gastrointestinal tumors.
Lamberts SW
Horm Res; 1988; 29(2-3):118-20. PubMed ID: 2900191
[TBL] [Abstract][Full Text] [Related]
28. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
[TBL] [Abstract][Full Text] [Related]
29. [Clinical use of octreotide (Sandostatin) in endocrinology].
Prelević GM
Med Pregl; 1993; 46(9-10):343-8. PubMed ID: 7997211
[TBL] [Abstract][Full Text] [Related]
30. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
31. Potential gastrointestinal uses of somatostain and its synthetic analogue octreotide.
Grosman I; Simon D
Am J Gastroenterol; 1990 Sep; 85(9):1061-72. PubMed ID: 1975156
[TBL] [Abstract][Full Text] [Related]
32. [Use of somatostatin analogue for intestinal and pancreatic fistulas].
Paran H; Neufeld D; Epstein T; Bendahan J; Freund U
Harefuah; 1991 Feb; 120(4):185-6. PubMed ID: 2066018
[TBL] [Abstract][Full Text] [Related]
33. [Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
Flückiger A; Schlup P
Schweiz Med Wochenschr; 1992 Aug; 122(33):1221-3. PubMed ID: 1326786
[TBL] [Abstract][Full Text] [Related]
34. Endocrine tumors of the gastrointestinal tract: systemic treatment.
Oberg K
Anticancer Drugs; 1994 Oct; 5(5):503-19. PubMed ID: 7858282
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma.
Schonfeld WH; Eikin EP; Woltering EA; Modlin IM; Anthony L; Villa KF; Zagari M
Int J Technol Assess Health Care; 1998; 14(3):514-25. PubMed ID: 9780538
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
[TBL] [Abstract][Full Text] [Related]
37. [Somatostatin analogs in oncology].
Thomas F; Parmar H; Prevost G; Kuhn JM; Bejot JL; Moreau JP; Bogden A
Bull Cancer; 1991; 78(8):693-707. PubMed ID: 1681967
[TBL] [Abstract][Full Text] [Related]
38. A guide to the clinical use of the somatostatin analogue SMS 201-995 (Sandostatin).
Lamberts SW
Acta Endocrinol Suppl (Copenh); 1987; 286():54-66. PubMed ID: 2892338
[TBL] [Abstract][Full Text] [Related]
39. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue.
Manfredi S; Pagenault M; de Lajarte-Thirouard AS; Bretagne JF
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):1021-5. PubMed ID: 18049175
[TBL] [Abstract][Full Text] [Related]
40. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
Tomassetti P; Migliori M; Corinaldesi R; Gullo L
Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
